Eli Lilly 8-K Report: Key Financial Insights & Debt Obligations as of Jan 14, 2025

Based on the provided XML section from the financial report, here are the key insights and important information extracted:

1. Entity Information:

• The entity involved is Eli Lilly and Company.
• CIK (Central Index Key) number: 0000059478.

2. Reporting Period:

• The report covers a single date: January 14, 2025.

3. Segment Information:

• The document references multiple classes of stock through the Statement Class of Stock Axis.

4. Debt Instruments: The company has several outstanding notes with various due dates and interest rates:

• 7 1/8% Notes due 2025 (LLY25)
• 1.625% Notes due 2026 (LLY26)
• 2.125% Notes due 2030 (LLY30)
• 0.625% Notes due 2031 (LLY31)
• 0.500% Notes due 2033 (LLY33)
• 6.77% Notes due 2036 (LLY36)
• 1.625% Notes due 2043 (LLY43)
• 1.700% Notes due 2049 (LLY49A)
• 1.125% Notes due 2051 (LLY51)
• 1.375% Notes due 2061 (LLY61)

5. Stock Information:

• Common stock has no par value and is listed under the ticker symbol LLY on the NYSE.

6. Corporate Details:

• Address: Lilly Corporate Center, Indianapolis, IN 46285.
• Contact Number: 317-276-2000.

7. Filing Type:

• This is an 8-K filing, indicating that it is a current report used to disclose important events that may affect the company’s financial condition.

Summary:

The report indicates a snapshot of Eli Lilly and Company's debt obligations as of January 14, 2025, detailing various notes with specific due dates and interest rates. The company’s common stock is listed on the NYSE, and the filing serves as a significant disclosure of financial obligations for investors and stakeholders.